Table S3.
The clinical therapeutic effects of the included studies
| Study | Treatment | Number of patients evaluated for efficacy | PR+CR (n) | SD+PD (n) |
|---|---|---|---|---|
| Sleijfer et al1 | Pazopanib | 138 | 9 | NA |
| van der Graaf et al10 | Pazopanib | 246 | 23 | 221 |
| Yoo et al2 | Pazopanib | 41 | 7 | 34 |
| Maki et al3 | Sorafenib | 122 | 6 | 116 |
| von Mehren et al4 | Sorafenib | 37 | 2 | 31 |
| Ray-Coquard et al5 | Sorafenib | 41 | 4 | 29 |
| Santoro et al6 | Sorafenib | 76 | 11 | 59 |
| Bramswig et al7 | Sorafenib | 20 | 4 | 16 |
| George et al8 | Sunitinib | 48 | 1 | 47 |
| Li et al9 | Sunitinib | 14 | 4 | 10 |
Abbreviations: NA, not available; PR, partial response; CR, complete response; SD, stable disease; PD, progressive disease.